GW gets $5 million high on Novartis deal for Sativex
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals (UK) has signed a licence deal with Novartis to commercialise its cannabis-based multiple sclerosis-related spasticity treatment Sativex in Australia, New Zealand, Asia (excluding Japan, China and Hong Kong), the Middle East (excluding Israel) and Africa.